Indian manufacturers will soon have the opportunity to work with the World Health Organization (WHO) COVID-19 Technology Access Pool (C-TAP) and Medicine Patent Pool (MPP) for innovative therapeutics, vaccines and coronavirus diagnostics.
MPP and C-TAP have finalized a licensing agreement with the United States National Institutes of Health (NIH) to develop a number of innovative therapeutics, early-stage vaccines, and diagnostic tools for COVID-19.
The announcement was made by the US government at the Second Global Covid-19 Summit, co-hosted by the United States, Belize, Germany, Indonesia and Senegal on Thursday.
Global and non-exclusive licenses will allow manufacturers around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries and to help end the epidemic.
The 11 COVID-19 technologies offered under the two licenses include the stabilized spike proteins currently used in the COVID-19 vaccine, research equipment for vaccines, therapeutic and diagnostic development, as well as early vaccine candidates and diagnostics.
“Whether today’s epidemic or tomorrow’s health is urgent, it is through sharing and empowering low-income countries to create their own healthcare equipment that we can ensure a healthier future for everyone,” said Dr. Tedros Adhanam Ghebreissus, WHO Director General.
“NIH shared their patent with MPP for an HIV product when we created it in 2010 and we are delighted to strengthen our partnership. It is clear that MPP’s model works across a variety of health technologies, “said Charles Gore, MPP’s executive director.
The licensing of NIH technology to MPP under the auspices of C-TAP will allow more access to these technologies that will lead to the development of commercial products that can meet current and future public health needs, the WHO said. In most cases, the NIH will not collect royalties on sales of licensed products in the 49 countries classified by the UN as Least Developed Countries.
Launched in 2020 by the WHO Director-General and the President of Costa Rica and supported by 43 member states, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products and increase their production and supply through open, transparent And non-exclusive licensing agreements. MPP provides licensing skills in this venture and holds licenses.
Read more: Cipla launches real-time RT-PCR test kit for COVID-19
Read more: India’s pharma logistics, warehousing costs 15% higher than other countries: report
Read more: India working to expand genomic surveillance consortium to neighboring countries: PM Modi